Table 5.
Lifetime costs, life-years, QALYs and incremental cost-effectiveness per true case of diabetes diagnosed
| Cost (US$) (discounted) | Health outcomes (discounted) | Incremental cost-effectiveness ratio | |||||
|---|---|---|---|---|---|---|---|
| Cost of treatment | Cost of complications | Cost of screening | Costs of intensified glycemic and hypertension control | Total costs | Remaining QALYs | Total cost/QALY (US$) | |
| No screening | 3015 | 911 | 0 | 344.967 | 4271 | 4.6436 | |
| Screening | 3308 | 888 | 35.965 | 528.104 | 4760 | 4.6593 | |
| Incremental | 292.378 | −22.478 | 36.965 | 183.137 | 489 | 0.0157 | 31,147 |
Brazilian nationwide population screening program for diabetes, 2001